Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies VI: Voiding Cystourethrography and Cystography01:22

Imaging Studies VI: Voiding Cystourethrography and Cystography

3.8K
Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...
3.8K
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

867
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
867

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Androgen Deprivation Therapy and Cardiovascular Health: Challenges and Opportunities in Prostate Cancer Care.

Archivos espanoles de urologia·2026
Same author

Baseline vulnerability over dosimetric precision: reframing late urinary toxicity after prostate stereotactic body radiotherapy.

Translational andrology and urology·2026
Same author

Prognostic Impact of Tumor Size in Low-Risk Upper Tract Urothelial Carcinoma: A Multi-Institutional Analysis.

The French journal of urology·2026
Same author

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

JNCI cancer spectrum·2026
Same author

[SAKK 09/10: dose-intensified salvage radiotherapy for biochemical recurrence after prostatectomy-no benefit, but additional toxicity?]

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Cell reports. Medicine·2026

Related Experiment Video

Updated: Apr 8, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Adjuvant Radiotherapy After Cystectomy in Muscle-Invasive Bladder Cancer: Indications, Benefits and Remaining

Patricia Valencia Nieto1, Fernando López-Campos2,3, Patricia Diezhandino García1

  • 1Radiation Oncology Department, Valladolid University Clinical Hospital, 47003 Valladolid, Spain.

Archivos Espanoles De Urologia
|April 7, 2026
PubMed
Summary

Adjuvant radiotherapy (ART) shows promise in reducing bladder cancer recurrence after surgery. This review explores ART

Keywords:
adjuvant radiotherapybladder cancerperioperative immunotherapyradical cystectomy

More Related Videos

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.4K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Experiment Videos

Last Updated: Apr 8, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.4K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Area of Science:

  • Urologic Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Bladder cancer is a significant global health issue, with muscle-invasive disease posing a high risk of recurrence post-radical cystectomy.
  • Locoregional recurrence remains a challenge despite neoadjuvant chemotherapy, limiting salvage options and impacting survival rates.
  • Adjuvant radiotherapy (ART) is being reconsidered for its potential to improve outcomes in high-risk bladder cancer patients.

Purpose of the Study:

  • To review the evolving role of adjuvant radiotherapy (ART) in the context of perioperative immunotherapy for muscle-invasive bladder cancer.
  • To critically examine the complementary value, toxicity, and patient selection for ART alongside modern systemic therapies.
  • To provide an updated synthesis of evidence and ongoing trials regarding ART in multimodal bladder cancer management.

Main Methods:

  • Narrative review synthesizing current evidence on adjuvant radiotherapy and perioperative immunotherapy for bladder cancer.
  • Analysis of recent clinical trials and reassessment of safety data, including findings from the BART trial.
  • Examination of emerging systemic strategies and their integration with radiotherapy in high-risk bladder cancer.

Main Results:

  • Perioperative immunotherapy (e.g., CheckMate 274, NIAGARA) is establishing a new standard of care for muscle-invasive bladder cancer.
  • Advances in radiotherapy techniques and re-evaluation of safety data support the potential role of ART.
  • The integration of ART with immunotherapy requires careful consideration of its complementary benefits and toxicity profile.

Conclusions:

  • Adjuvant radiotherapy may offer a valuable strategy for reducing locoregional recurrence and improving metastasis-free survival in select bladder cancer patients.
  • Optimal incorporation of ART into multimodal treatment requires careful patient selection and consideration of its role alongside novel immunotherapy regimens.
  • Further research and ongoing trials are crucial to define the precise role and optimal application of ART in the current immunotherapy era for high-risk bladder cancer.